Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Peter Norman. (2014) Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013. Expert Opinion on Therapeutic Patents 24:5, pages 573-595.
Read now
Read now
Ronald J. Hill, Yan Lou & Seng-Lai Tan. (2013) B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities. International Reviews of Immunology 32:4, pages 377-396.
Read now
Read now
Mercedes González & Hugo Cerecetto. (2012) Quinoxaline derivatives: a patent review (2006 – present). Expert Opinion on Therapeutic Patents 22:11, pages 1289-1302.
Read now
Read now
Jorge Morales-Torres. (2012) The status of fostamatinib in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 8:7, pages 609-615.
Read now
Read now
Articles from other publishers (35)
Mohammad Shadab, Spencer A. Slavin, Zahra Mahamed, Michelle W. Millar, Rauf A. Najar, Antony Leonard, Anthony Pietropaoli, David A. Dean, Fabeha Fazal & Arshad Rahman. (2023) Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury. Journal of Biological Chemistry 299:12, pages 105408.
Crossref
Crossref
Bingbing Cui, Yong Wang, Zhipeng Zhao, Lu Fan, Yu Jiao, Hongmei Li, Jie Feng, Weifang Tang, Tao Lu & Yadong Chen. (2023) Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1H-pyrazol-4 -amine derivatives as novel and potent syk inhibitors for the treatment of hematological malignancies. European Journal of Medicinal Chemistry 258, pages 115597.
Crossref
Crossref
Rakesh Sahu, Kamal Shah, Yash Gautam & Kaushilya Sahu. (2023) Pyrazine Moiety: Recent Developments in Cancer Treatment. Current Organic Chemistry 27:10, pages 821-843.
Crossref
Crossref
Boyang Yu, Boye Li, Tian Chen, Jinning Yang, Xiaoli Wang, Bo Peng & Qin Hu. (2022) A NF-κB-Based High-Throughput Screening for Immune Adjuvants and Inhibitors. Inflammation 46:2, pages 598-611.
Crossref
Crossref
Himangshu Sonowal, William G. Rice & Stephen B. Howell. (2023) Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma. PLOS ONE 18:3, pages e0277003.
Crossref
Crossref
Quanwei Zhou, Min Wei, Wenyue Shen, Sheng Huang, Jianfeng Fan & He Huang. (2022) SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma. Frontiers in Genetics 13.
Crossref
Crossref
Supriya ChakrabortyClaudio Martines, Fabiola Porro, Ilaria FortunatiAlice Bonato, Marija DimishkovskaSilvano Piazza, Brijesh S. Yadav, Idanna InnocentiRosa FazioTiziana Vaisitti, Silvia Deaglio, Alberto Zamò, Aleksandar J. DimovskiLuca Laurenti & Dimitar G. Efremov. (2021) B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. Blood 138:12, pages 1053-1066.
Crossref
Crossref
Yuehong Chen, Huan Liu, Yupeng Huang, Sang Lin, Geng Yin & Qibing Xie. (2021) The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Sameer P. Kawatkar, Bernard Barlaam, Paul Kemmitt, Iain Simpson, David Watson, Peng Wang, Scott Lamont, Qibin Su, Scott Boiko, Timothy Ikeda, Joe Patel, Andy Pike, Hannah Pollard, Jon Read, Ujjal Sarkar, Haiyun Wang, Quanshan Wen, Zhiyuan Yan, James E. Dowling, Hannah Dry & Scott D. Edmondson. (2020) Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 30:18, pages 127393.
Crossref
Crossref
Joseph P. Loftus, Anella Yahiaoui, Patrick A. Brown, Lisa M. Niswander, Asen Bagashev, Min Wang, Allyson Schauf, Stacey Tannheimer & Sarah K. Tasian. (2020) Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. Haematologica 106:4, pages 1067-1078.
Crossref
Crossref
Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang & Yan Fan. (2020) Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. Bioorganic Chemistry 95, pages 103547.
Crossref
Crossref
Solène Fernandez, Vanessa Desplat, Arnaud Villacreces, Amélie V. Guitart, Noël Milpied, Arnaud Pigneux, Isabelle Vigon, Jean-Max Pasquet & Pierre-Yves Dumas. (2019) Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. International Journal of Molecular Sciences 20:14, pages 3429.
Crossref
Crossref
Shuxin Sun, Dongdong Xue, Zhijie Chen, Ying Ou-yang, Ji Zhang, Jialuo Mai, Jiayv Gu, Wanjun Lu, Xincheng Liu, Wenfeng Liu, Longxiang Sheng, Bingzheng Lu, Yuan Lin, Fan Xing, Zhongping Chen, Yonggao Mou, Guangmei Yan, Wenbo Zhu & Ke Sai. (2019) R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells. Cell Death & Disease 10:5.
Crossref
Crossref
Kodappully S. Siveen, Kirti S. Prabhu, Iman W. Achkar, Shilpa Kuttikrishnan, Sunitha Shyam, Abdul Q. Khan, Maysaloun Merhi, Said Dermime & Shahab Uddin. (2018) Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. Molecular Cancer 17:1.
Crossref
Crossref
Chao Feng, Amitava Roy & Carol Beth Post. (2018) Entropic allostery dominates the phosphorylation-dependent regulation of Syk tyrosine kinase release from immunoreceptor tyrosine-based activation motifs. Protein Science 27:10, pages 1780-1796.
Crossref
Crossref
Gerald Moncayo, Michal Grzmil, Tatiana Smirnova, Pawel Zmarz, Roland M Huber, Debby Hynx, Hubertus Kohler, Yuhua Wang, Hans-Rudolf Hotz, Nancy E Hynes, Georg Keller, Stephan Frank, Adrian Merlo & Brian A Hemmings. (2018) SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. Neuro-Oncology 20:5, pages 621-631.
Crossref
Crossref
Srini Ramanathan, Julie A. Di Paolo, Feng Jin, Lixin Shao, Shringi Sharma, Michelle Robeson & Brian P. Kearney. (2016) Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. Clinical Drug Investigation 37:2, pages 195-205.
Crossref
Crossref
Betty Lam, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher, Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky & Zhe Nie. (2016) Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorganic & Medicinal Chemistry Letters 26:24, pages 5947-5950.
Crossref
Crossref
A. Peter Hall, T. Mitchard, M. G. Rolf, J. Stewart & P. Duffy. (2016) Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment. Toxicologic Pathology 44:6, pages 866-873.
Crossref
Crossref
Gregory D. Ferguson, Mercedes Delgado, Veronique Plantevin-Krenitsky, Kristen Jensen-Pergakes, R. J. Bates, Sanaa Torres, Maria Celeridad, Heather Brown, Kelven Burnett, Lisa Nadolny, Lida Tehrani, Garrick Packard, Barbra Pagarigan, Jason Haelewyn, Trish Nguyen, Li Xu, Yang Tang, Matthew Hickman, Frans Baculi, Steven Pierce, Keiji Miyazawa, Pilgrim Jackson, Philip Chamberlain, Laurie LeBrun, Weilin Xie, Brydon Bennett & Kate Blease. (2016) A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation. PLOS ONE 11:1, pages e0145705.
Crossref
Crossref
Terry King-Wing Ma, Stephen P. McAdoo & Frederick Wai-Keung Tam. (2016) Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. Nephron 133:4, pages 261-269.
Crossref
Crossref
Frank Lovering, Cristina Aevazelis, Jeanne Chang, Christoph Dehnhardt, Lori Fitz, Seungil Han, Kristin Janz, Julie Lee, Neelu Kaila, Joseph McDonald, William Moore, Alessandro Moretto, Nikolaos Papaioannou, David Richard, Mark S. Ryan, Zhao-Kui Wan & Atli Thorarensen. (2016) Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP). ChemMedChem 11:2, pages 217-233.
Crossref
Crossref
Ruth-Miriam Koerber, Stefanie Andrea Erika Held, Annkristin Heine, Philipp Kotthoff, Solveig Nora Daecke, Anita Bringmann & Peter Brossart. (2015) Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Experimental Hematology & Oncology 4:1.
Crossref
Crossref
Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y. Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing-Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon & Robert Z. Orlowski. (2015) Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clinical Cancer Research 21:11, pages 2538-2545.
Crossref
Crossref
Tatiana PerovaIldiko GrandalLauryl M. J. NutterEniko PappIrina R. MateiJoseph BeyenePaul E. KowalskiJohann K. HitzlerMark D. MindenCynthia J. GuidosJayne S. Danska. (2014) Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine 6:236.
Crossref
Crossref
Qingqing Cai, Jason Westin, Kai Fu, Madhav Desai, Liang Zhang, Huiqiang Huang, Wenqi Jiang, Rong Liang, Zhengzi Qian, Richard E. Champlin & Michael Wang. (2013) Accelerated therapeutic progress in diffuse large B cell lymphoma. Annals of Hematology 93:4, pages 541-556.
Crossref
Crossref
Jing-Yuan Chuang, Yuan-Li Huang, Wei-Lin Yen, I-Ping Chiang, Ming-Hsui Tsai & Chih-Hsin Tang. (2014) Syk/JNK/AP-1 Signaling Pathway Mediates Interleukin-6-Promoted Cell Migration in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences 15:1, pages 545-559.
Crossref
Crossref
Shivaani Kummar, Anthony J. Murgo, Joseph E. Tomaszewski & James H. Doroshow. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
423
433.e2
.
Carsten U. Niemann & Adrian Wiestner. (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Seminars in Cancer Biology 23:6, pages 410-421.
Crossref
Crossref
Seng-Lai Tan, Cheng Liao, Matthew C. Lucas, Christopher Stevenson & Julie A. DeMartino. (2013) Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders. Pharmacology & Therapeutics 138:2, pages 294-309.
Crossref
Crossref
Frank Lovering, Joseph McDonald, Gavin A. Whitlock, Paul A. Glossop, Chris Phillips, Andrew Bent, Yogesh Sabnis, Mark Ryan, Lori Fitz, Julie Lee, Jeanne S. Chang, Seungil Han, Ravi Kurumbail & Atli Thorarensen. (2012) Identification of Type-II Inhibitors Using Kinase Structures. Chemical Biology & Drug Design 80:5, pages 657-664.
Crossref
Crossref
CHONG YAN, CHIBO LIU, QIAOZHI JIN, ZHIHAI LI, BAOHONG TAO & ZHIYI CAI. (2012) The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines. Oncology Letters 4:3, pages 505-508.
Crossref
Crossref
NEELU KAILA, MARK S. RYAN, ATLI THORARENSEN & EDDINE SAIAH. 2012. Anti-Inflammatory Drug Discovery. Anti-Inflammatory Drug Discovery
181
210
.
Rajinder Singh, Esteban S. Masuda & Donald G. Payan. (2012) Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. Journal of Medicinal Chemistry 55:8, pages 3614-3643.
Crossref
Crossref
Freda K. Stevenson, Sergey Krysov, Andrew J. Davies, Andrew J. Steele & Graham Packham. (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118:16, pages 4313-4320.
Crossref
Crossref